


Medtronic Inc.s experimental spinal device may face a battle for U.S. regulatory approval after a narrow 6-5 vote from a federal advisory panel that the devices benefits outweigh its risks.
Read more...Medtronic Inc.s experimental spinal device may face a battle for U.S. market approval after an advisory panel voted 6 to 5 that the devices benefits outweigh its risks.
Read more...But a 6-5-3 vote suggests that some concerns linger about the bone-growth device Amplify and a possible link to cancer.
Read more...